#Sweden #Stockholm #MGI Tech #VisiOmics #ECP 2026

MGI Tech Unveils VisiOmics and AI Pathology Solutions at ECP 2026

Introduction
MGI Tech Co., Ltd., a leading innovator in life science tools, took a momentous step in advancing pathology research by launching its fully automated system, VisiOmics, at the 38th European Congress of Pathology (ECP 2026) held in Stockholm. This announcement, made on September 15, 2026, highlights the company’s commitment to integrating advanced technology in healthcare diagnostics.

VisiOmics: A Game Changer in Pathology
VisiOmics marks a significant leap forward in the field of tissue and molecular pathology. With a focus on the theme “From Tissue to Answer,” this system supports the complex needs of researchers by enabling high-plex protein marker detection in a single tissue section. The technology allows for the analysis of over 20 protein markers simultaneously, with the potential to expand this to over 100 through the innovative use of cyclic staining techniques.

This automated staining and imaging system facilitates multiplex detection, drastically streamlining laboratory workflows. As researchers increasingly probe the spatial organization of cell populations within tissues, VisiOmics stands to elevate the quality and efficiency of analysis:

• - High-throughput capabilities: The system can automatically handle the entire staining-to-imaging workflow, allowing scientists to focus on data analysis instead of manual processes.
• - AI-Enhanced Image Analysis: Equipped with FluoXpert Vision, VisiOmics harnesses AI to automate crucial image analysis steps, including cell segmentation and phenotyping. This feature simplifies data visualization, making it more accessible to a range of users.

Fang Chen, Vice President at MGI and General Manager for Europe and Africa, remarked, “Pathology research is increasingly combining morphological assessment with multiplex spatial proteomics. With VisiOmics available in Europe, we are excited to provide a comprehensive pipeline from tissue analysis to diagnostic answers.”

Strategic Collaborations and Innovations
MGI is also engaging in a partnership with the Fraunhofer Institute for Integrated Circuits IIS, aimed at demonstrating how images from VisiOmics can seamlessly integrate into existing workflows using MIKAIA®, a sophisticated image analysis software. This collaboration emphasizes the flexibility and potential of VisiOmics data, showcasing how it can serve a variety of research needs.

Additionally, MGI introduced the Path-P96 WF system – a customizable platform designed to support the high-throughput generation of well-characterized tissue image datasets. It processes up to 32 slides simultaneously and covers various profiles needed for advanced drug discovery and spatial biology initiatives.

Molecular Pathology Solutions
Expanding its portfolio, MGI also presented PrepLPS (PrepALL Library Prep Edition), a liquid-handling platform for next-generation sequencing (NGS) library preparation, along with the AIO (All-in-One) platform, which consolidates the entire workflow from sample to result in just over 11 hours. This innovation streamlines the library preparation and reporting process, making it far more efficient for labs eager to expedite their research timelines.

The Role of AI in MGI's Innovations
Across all these platforms, MGI highlights a significant trend: the incorporation of AI into its systems, creating a cohesive user experience. The AI-powered features from image analysis to workflow orchestration can drastically enhance laboratory efficiency and research capabilities. Each technological component, whether it’s FluoXpert Vision for image analysis or machine-vision monitoring on PrepALL, is designed with end-users in mind, fostering an intelligent lab environment.

About MGI
Founded in 2016, MGI Tech Co., Ltd. has established itself as a significant player in the life sciences sector. The company is distinguished for its ability to independently develop and mass-produce clinical-grade gene sequencers, supporting a diverse range of sequencing capabilities. MGI is committed to fostering innovation through its three core segments: SEQ ALL for sequencing, GLI for generative lab intelligence, and Multi-Omics.

Further information is available through various platforms, including its official website, LinkedIn, and other social media channels.

Conclusion
With the launch of VisiOmics and the introduction of its comprehensive pathology tools at ECP 2026, MGI Tech is well-positioned to lead the advancement of diagnostic research. Its focus on AI integration not only simplifies complex processes but also empowers researchers with powerful tools to transform pathology as we know it. As the landscape of medical diagnostics evolves, MGI—bolstered by strategic partnerships and an innovative mindset—will likely remain at the forefront of this transformative journey.